DrugPatentWatch Database Preview
Patent: 9,086,418
» See Plans and Pricing
Summary for Patent: 9,086,418
| Title: | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| Abstract: | The invention provides a method for determining the efficacy of a TNF.alpha. inhibitor, such as a TNF.alpha. antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker. |
| Inventor(s): | Maksymowych; Walter P. (Edmonton, CA), Wong; Robert L. (Basking Ridge, NJ) |
| Assignee: | ABBVIE BIOTECHNOLOGY LTD. (Hamilton, BM) |
| Application Number: | 13/034,809 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,086,418
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | HUMIRA | adalimumab | VIAL | 125057 | 002 | 2002-12-31 | Start Trial | ABBVIE BIOTECHNOLOGY LTD. (Hamilton, BM) | 2021-03-07 | RX | Orphan | search |
| Abbvie Inc | HUMIRA | adalimumab | SYRINGE | 125057 | 001 | 2002-12-31 | Start Trial | ABBVIE BIOTECHNOLOGY LTD. (Hamilton, BM) | 2021-03-07 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,086,418
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007089303 | Start Trial |
| United States of America | 2007172897 | Start Trial |
| United States of America | 2012129185 | Start Trial |
| United States of America | 7919264 | Start Trial |
| Taiwan | 200736611 | Start Trial |
| Taiwan | 201337266 | Start Trial |
| Taiwan | I424161 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
